While most NSCLC cases do not present with additional driver mutations, analysis of over 4,871 samples by Kato and colleagues identified co-occurrence of RET fusions with other genetic alterations, such as PI3K-associated genes or MAPK effector genes, in up to 82% (72/88) of NSCLC patients (41). The gene discussed is RET; the disease is non-small cell lung carcinoma.